GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 14, 2024 08:05 ET
|
GRI Bio, Inc.
Company focused on execution of lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) GRI-0621 interim data readout of Phase 2a biomarker study on track for Q4 2024 and...
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series
July 15, 2024 09:05 ET
|
GRI Bio, Inc.
Live video webcast on Wednesday, July 17th at 12:00 PM ET LA JOLLA, CA, July 15, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio,” “we,” “our,” or the “Company”), a...
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment
July 11, 2024 09:20 ET
|
GRI Bio, Inc.
Marc Hertz, PhD, CEO of GRI Bio underscores importance of the interim data from their ongoing Phase 2a biomarker study for Idiopathic Pulmonary Fibrosis (IPF) LA JOLLA, CA, July 11, 2024 (GLOBE...
GRI Bio Regains Compliance with Nasdaq
July 08, 2024 09:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine
July 02, 2024 09:05 ET
|
GRI Bio, Inc.
Data demonstrates that NKT cells are activated in airways in IPF patients and inhibition of type 1 invariant NKT (iNKT) cell activity can ameliorate bleomycin-induced pulmonary fibrosis in mice ...
GRI Bio to Present at the 8th Annual IPF Summit
July 01, 2024 08:45 ET
|
GRI Bio, Inc.
LA JOLLA, CA, July 01, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Closing of $4.0 Million Public Offering
June 28, 2024 16:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, June 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators
June 27, 2024 09:00 ET
|
GRI Bio, Inc.
Company is strategically building a global patent estate in key territories for a growing pipeline targeting potentially high-value indications in need of innovation LA JOLLA, CA, June 27, 2024 ...
GRI Bio Announces Pricing of $4 Million Public Offering
June 27, 2024 08:00 ET
|
GRI Bio, Inc.
LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
GRI Bio Announces Reverse Stock Split
June 14, 2024 08:05 ET
|
GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...